# XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer

> **NCT00417079** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 755 (actual)

## Conditions studied

- Neoplasms
- Prostatic Neoplasms

## Interventions

- **DRUG:** cabazitaxel (XRP6258) (RPR116258)
- **DRUG:** mitoxantrone
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT00417079
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 755 (ACTUAL)
- **Last updated:** 2011-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417079, "XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00417079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*